Stock Events

Stock Events

Genmab 

€235.4
229
+€1.4+0.6% Today

Statistics

Day High
237.3
Day Low
234
52W High
301.4
52W Low
171.1
Volume
40
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
0.42
1.07
1.72
2.37
Expected EPS
1.32894669784
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GE9.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Roche
RHHBY
Mkt Cap328.49B
Roche Holding AG is a major player in biotechnology, directly competing with Genmab in the development of monoclonal antibodies and cancer treatments.
AMGEN
AMGN
Mkt Cap178B
Amgen Inc. competes in the biotech space, focusing on innovative therapeutics, including those for cancer, which overlaps with Genmab's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals, Inc. is known for its work in monoclonal antibodies, directly competing with Genmab in several therapeutic areas.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, Inc. operates in the biopharmaceutical field, competing with Genmab in the development of treatments for diseases such as cancer.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb Company competes with Genmab in the oncology sector, particularly in the development of innovative cancer treatments.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. is a global healthcare company that competes with Genmab in the development of cancer therapies and immunotherapy treatments.
Novartis
NVS
Mkt Cap279.67B
Novartis AG competes with Genmab in the pharmaceutical and biotechnology sectors, particularly in the development of innovative medicines, including cancer treatments.
Pfizer
PFE
Mkt Cap149.77B
Pfizer Inc. is a global pharmaceutical company that competes with Genmab in the development of drugs for various diseases, including cancer.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca PLC is involved in the discovery and development of pharmaceuticals for several diseases, including cancer, making it a competitor to Genmab.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson operates in the pharmaceutical and biotechnology sectors, competing with Genmab in the development of innovative treatments for diseases, including cancer.

About

There is no Profile data available for GE9.SG.
Show more...
CEO
Country
Denmark
ISIN
DK0010272202

Listings

MX
MX
GMABN.MX
CO
DK
GMAB.CO
STU
DE
GE91.STU
STU
DE
GE9.STU

0 Comments

Share your thoughts

FAQ

What is Genmab stock price today?▼
The current price of GE9.STU is €235.4 EUR — it has increased by +0.6% in the past 24 hours. Watch Genmab stock price performance more closely on the chart.
What is Genmab stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Genmab stocks are traded under the ticker GE9.STU.
Is Genmab stock price growing?▼
GE9.STU stock has risen by +5.94% compared to the previous week, the month change is a -0.34% fall, over the last year Genmab has showed a +24.16% increase.
When is the next Genmab earnings date?▼
Genmab is going to release the next earnings report on May 07, 2026.
What were Genmab earnings last quarter?▼
GE9.STU earnings for the last quarter are 0.42 EUR per share, whereas the estimation was 2.37 EUR resulting in a -82.28% surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Genmab located?▼
Genmab operates in the Materials sector.
When did Genmab complete a stock split?▼
Genmab has not had any recent stock splits.